FeesSafety
Pluang+

60% of CCOs say communications functions lag behind their leadership roles, needing better systems and resources.

Others
22 Oct 2026
The Grossman Group
View Source
Neutral
60% of CCOs say communications functions lag behind their leadership roles, needing better systems and resources.

A new study by The Grossman Group reveals that while 60% of chief communications officers (CCOs) have influence at the leadership level, their communications functions lack the necessary systems, skills, and AI capabilities to fully meet their mandates. Most CCOs report strong CEO support but face challenges like flat or declining budgets and gaps in measurement that satisfy CFOs. Newer CCOs prioritize foundational improvements such as strategy and talent. The study highlights the need for communications functions to modernize operationally to match their strategic influence.

The topic of communications functions and their evolving challenges is noted here with Pluang's media sector data as context. For readers following media stocks, here is Pluang's market snapshot as of Oct 22, 2026 21:11 WIB: Of 58 priced US media stocks, 39 rose and 17 fell today. Comcast Corporation (CMCSA) traded at USD 23.07, up 4.46%, with Pluang order activity showing 39% sell and 61% buy, and a typical hold time of 94 days. AST SpaceMobile Inc (ASTS) was priced at USD 39.29, down 3.94%, with 68% sell and 32% buy activity, holding typically for 34 days. EchoStar Corporation (ECHO) stood at USD 89.10, down 3.82%, with 0% sell and 100% buy activity, and a typical hold time of 6 days.

More News

Over 200 companies advance 240+ Alzheimer's drugs, marking a new phase in treatment development

Over 200 companies advance 240+ Alzheimer's drugs, marking a new phase in treatment development

More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...

Market News
Bullish
11 minutes ago
Sagimet Biosciences starts key Phase 3 trial for acne drug denifanstat in the U.S.

Sagimet Biosciences starts key Phase 3 trial for acne drug denifanstat in the U.S.

Sagimet Biosciences has initiated a crucial Phase 3 clinical trial in the U.S. for denifanstat, an oral treatment targeting moderate to severe acne. The trial, named AURORA, aims to enroll around 800 patients, including adolescents, to support regula...

Market News
Bullish
1 hour ago
Nokia beats Q3 earnings and revenue estimates with strong AI and cloud sales growth.

Nokia beats Q3 earnings and revenue estimates with strong AI and cloud sales growth.

Nokia reported third-quarter 2026 earnings per share of $0.10, surpassing the $0.08 estimate, and revenue of $5.78 billion, exceeding the $5.72 billion forecast. The company's AI and cloud sales surged 123%, driven by high demand for its IP Networks ...

Company Fundamentals
Bullish
1 hour ago
RingCentral set to report Q3 2026 earnings with expected EPS of $1.27-$1.28 and $667M revenue.

RingCentral set to report Q3 2026 earnings with expected EPS of $1.27-$1.28 and $667M revenue.

RingCentral will announce its Q3 2026 earnings on October 22, with analysts forecasting earnings per share between $1.27 and $1.28 and revenue around $667 million. This represents a 12.4% increase in earnings and 4.4% growth in revenue compared to th...

Company Fundamentals
Neutral
1 hour ago
Mortgage rates drop to 7.32%, easing costs for homebuyers this week.

Mortgage rates drop to 7.32%, easing costs for homebuyers this week.

Freddie Mac reported that the average 30-year fixed mortgage rate fell to 7.32% as of October 22, 2026, down from 7.40% the previous week. This decline offers some relief to prospective homebuyers facing higher borrowing costs compared to last year, ...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App